Eli Lilly and Company Stock

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-04-22 pm EDT 5-day change 1st Jan Change
731.3 USD +0.69% Intraday chart for Eli Lilly and Company -2.59% +25.46%
Sales 2024 * 41.36B Sales 2025 * 51.29B Capitalization 654B
Net income 2024 * 10.89B Net income 2025 * 15.79B EV / Sales 2024 * 16.2 x
Net Debt 2024 * 15.19B Net Debt 2025 * 10.74B EV / Sales 2025 * 13 x
P/E ratio 2024 *
59.8 x
P/E ratio 2025 *
40.5 x
Employees 43,000
Yield 2024 *
0.71%
Yield 2025 *
0.82%
Free-Float 99.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.69%
1 week-2.59%
Current month-5.99%
1 month-5.10%
3 months+15.92%
6 months+26.82%
Current year+25.46%
More quotes
1 week
722.07
Extreme 722.07
771.83
1 month
722.07
Extreme 722.07
793.67
Current year
579.05
Extreme 579.05
800.78
1 year
370.68
Extreme 370.68
800.78
3 years
178.58
Extreme 178.5779
800.78
5 years
101.36
Extreme 101.36
800.78
10 years
57.35
Extreme 57.35
800.78
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 95-12-31
Director of Finance/CFO 51 00-12-31
President - -
Members of the board TitleAgeSince
Director/Board Member 63 21-01-24
Director/Board Member 67 09-03-31
Director/Board Member 63 04-12-31
More insiders
Date Price Change Volume
24-04-22 731.3 +0.69% 2,264,027
24-04-19 726.3 -2.63% 3,505,526
24-04-18 746 -0.64% 1,717,347
24-04-17 750.8 +0.54% 3,069,367
24-04-16 746.7 -0.54% 2,569,799

Delayed Quote Nyse, April 22, 2024 at 04:00 pm EDT

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
726.3 USD
Average target price
813.3 USD
Spread / Average Target
+11.98%
Consensus